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Biological validation of new radiotherapy modalities is essential to understand their therapeutic potential.
Antiprotons have been proposed for cancer therapy due to enhanced dose deposition provided by
antiproton-nucleon annihilation. We assessed cellular DNA damage and relative biological effectiveness
(RBE) of a clinically relevant antiproton beam.Despite amodest LET (,19 keV/mm), antiproton spread out
Bragg peak (SOBP) irradiation caused significant residual c-H2AX foci compared to X-ray, proton and
antiproton plateau irradiation. RBE of,1.48 in the SOBP and,1 in the plateauweremeasured and used for
a qualitative effective dose curve comparison with proton and carbon-ions. Foci in the antiproton SOBP
were larger and more structured compared to X-rays, protons and carbon-ions. This is likely due to
overlapping particle tracks near the annihilation vertex, creating spatially correlated DNA lesions. No
biological effects were observed at 28–42 mm away from the primary beam suggesting minimal risk from
long-range secondary particles.
I
t is commonly acknowledged that a significant improvement in cancer radiotherapy requires both a better
control of energy deposition and a greater knowledge of the biological response of the irradiated tissues.
Charged particles (Hadron-therapy) have been suggested for cancer treatment, and are currently being used
with impressive results in clinics worldwide, because they exhibit an inverse depth-dose profile with most of their
energy deposited at the end of the particle track in what is known as the ‘Bragg peak’. Compared to conventional
Mega Voltage (MV) X-ray radiotherapy, hadron-therapy offers a clear dosimetric advantage as it allows a
reduction of the integral dose to healthy tissue by a factor of 2–31.Moreover, unlike X-rays, the biological response
of samples exposed to charged particle beams changes as particles slow down as they penetrate the sample. This
could be further exploited for radiotherapy purposes as enhanced biological effectiveness is expected in the final
part of the particle track due to the increasing Linear Energy Transfer (LET). Protons are generally considered to
have a similar biological effectiveness to photons (Relative Biological Effectiveness, RBE 5,1.1). Therefore the
main advantage of using protons is the possibility of delivering a lethal tumour dose with minimal dose to
surrounding healthy tissue, thus reducing the risk of adverse effects. Consequently, protons are prescribed for
treatment of tumours near high-risk tissues such as the spinal cord and are predicted to have the best advantage
for treatment of rare pediatric cancers. In those cases the ability to minimise healthy tissue damage and dose to
developing organs is critical2,3.
In the case of heavier ion beams such as carbon ions an additional advantage is provided by the increased
ionization density of the final part of the ion track4. The subsequent damage to critical cellular targets, primarily
DNA, is therefore more challenging to repair and results in higher biological effectiveness. The LET increases
significantly as carbon ions slow down, making these ions 2–5 times more effective per unit dose absorbed
compared to photons (and protons)5–7. In addition, high-LET radiation has been demonstrated in numerous
in vitro experiments to be more effective than low-LET-radiation for the treatment of radiation resistant and
hypoxic tumours8. Unfortunately, heavy ions also have a higher RBE in the entrance channel compared to X-rays
and low LET particles thereby presenting an increased damage risk for healthy tissues in the entrance channel.
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RBE range for cell killing in vitro in the entrance channel of 100–
270 MeV/u carbon ions is 1 to 1.755,7,9,10. However, since the most
substantial increase in RBE is found at the distal end of the particle
track, i.e. within the tumour, this leads to a net therapeutic advantage,
which forms the radiobiological rationale for carbon-ion therapy.
Like proton and carbon ion beams, antiprotons display a distinct
Bragg peak11–14. Given that they have an identical mass and equal,
but opposite, charge to protons, antiprotons interact with matter,
through Coulomb interactions; in the same way as protons do and
are therefore characterized by a low LET proximal to the Bragg peak,
i.e. in the therapeutic entrance channel. However, the ratio of phys-
ical doses deposited in the Bragg peak versus the plateau of an anti-
proton beam is approximately twice that of the equivalent proton
beam. This is due to antiproton-nucleon annihilation in the target
matter as the antiprotons come to rest. Of the resulting ,2 GeV
released by the annihilation event, approximately 30 MeV is depos-
ited near the point of annihilation by high LET nuclear fragments15.
Augmentation of LET by these nuclear fragments has been suggested
to increase the biological effectiveness at the antiproton Bragg peak
(as for carbon ions). Conversely, antiprotons can be expected to have
similar properties to protons in the plateau with a modest, if any,
increase in the RBE16,17 as the particle slows down. The remainder of
the 2 GeV produced by each antiproton annihilation radiates away
from the annihilation point in the form of pions and gamma rays.
Recent proof-of-principal experiments suggest that these pions may
be used for real-time imaging of antiproton annihilation events in
tissues providing ‘‘live’’ dose monitoring and targeting options.
These studies indicate that dose verification to ,1 mm accuracy
would be possible within a therapeutic dose range18,19. However,
concerns about this long range secondary radiation have been raised
as it would inevitably decrease the resolution of the dose deposition
profiles which is one of themain advantages of ion beam therapy20–22.
It is however, recognized that the resolution of the dose profiles will
have to be assessed for the biological effective dose, including RBE
profiles, requiring detailed investigations of the biological conse-
quences of antiproton exposures.
Only then can we precisely assess the risks and potentials of anti-
matter beams. To this purpose, we have studied the response of
normal human fibroblast cells to antiproton exposure along the par-
ticle path and in its immediate surroundings. DNA damage and cell
killing induced by the products of the antiproton-annihilation are
compared with those caused by other ion beams, photons and out-of
field effects in cells not traversed by the primary antiproton beam but
exposed mainly to long range secondary particles.
Results
Antiproton annihilation causes spatially correlated DNAdamage.
In order to assess if antiprotons induce DNA damage of different
quantity and quality to other radiation modalities, DNA double
strand breaks (DSBs) were analyzed in irradiated cell nuclei at 1
and 26 h post irradiation. DNA DSBs were visualized by
immunostaining for phospho-serine 139 histone 2AX (c-H2AX)
(Fig. 1.a), a marker of DNA DSBs23. Fluorescence imaging of c-
H2AX foci indicated that antiproton SOBP irradiated nuclei
contained foci that were larger than X-ray, proton, or carbon-ion
irradiated samples at 1 h (full width at half maximum fluorescence
Figure 1 | Initial and residual c-H2AX foci were observed in charged particle irradiated fibroblasts. (a) c-H2AX foci (green) were imaged at 1 and 26 h
after irradiation with antiprotons (top), carbon ions, protons or 225 kVp X-rays. (b) ‘Cut-view’ images taken from compiled Z-stack images through
irradiated cells show stacks of foci along antiproton paths in SOBP irradiated cells that were fixed 1 h after irradiation. (c) Restoration deconvolution was
applied to images of cell nuclei from antiproton-irradiated fibroblasts. Antiproton SOBP irradiated nuclei (top) contained large clustered foci that were
smaller and less frequent in antiproton plateau irradiated fibroblasts (bottom).
www.nature.com/scientificreports
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intensity (FWHM) 5 1.58 6 0.13 mm for antiproton SOBP against
1.26 6 0.07 mm for carbon-ion SOBP and 0.79 6 0.08 mm for
protons) and significantly larger (P , 0.0001 and P 5 0.0005
respectively) at 26 h (FWHM 5 1.65 6 0.12 mm for antiprotons
against 0.95 6 0.07 mm for the carbon SOBP and 1.13 6 0.07 mm
for protons) post-irradiation. Results of high-resolution imaging
combined with restoration-deconvolution indicated that the large
c-H2AX foci observed in the nuclei of antiproton Bragg peak
irradiated cells consisted of multiple micro-foci units (Fig. 1.c).
The larger foci produced by the antiproton annihilation events
appear therefore to be clusters of individual but spatially and
temporally correlated DNA lesions as characteristic of high LET
radiation. Imaging nuclei through fine Z-stacks also revealed that
both antiproton and carbon-ion SOBPs produce elongated foci,
which extend along the particle track in the direction of the
particle beams. Although it was not possible to distinguish
individual foci along the particle track, this is clearly the result of a
series of DNA DSBs caused by the high ionization density near the
Bragg peaks. This effect was not observed in samples exposed to X-
ray, proton and antiproton in the plateau where all foci appear as
isolated small units (Fig. 1.b).
As in the case of any particle exposures, at microscopic level there
will be dose inhomogeneity with a high amount of energy deposited
along the particle track and less by the secondary electrons. This is
accentuated in the case of heavy ions such as carbon and similar
situations are expected at the site of annihilation. As the annihilation
occurs predominantly at the end of the antiproton range, the fre-
quency of annihilation per cell depends on the position of the cell
within the SOBP and weighted energy spread. For the experiment
reported, in the middle of the SOBP (average LET 5 19 keV/mm), a
cell will experience ,50 antiproton traversals per Gy. Based on the
fact that 7 different beam energies (120–126 MeV, step,1 MeV) are
used to modulate the SOBP, ,10% of these antiprotons (i.e. ,5
antiproton annihilation/cell per Gy) will annihilate in cells around
the centre of the SOBP.
Foci size and repair kinetics.Quantification of DNA damage foci at
1 h post-irradiation showed that all radiationmodalities investigated
had a linear dose-response relationship within the LET range
considered (4–150 keV/mm) (see SI Fig. S1).
At 1 h after irradiation there is no statistically significant change in
the mean number of foci/Gy/cell as a function of LET (Fig. 2.a).
However, because repair will have begun minutes after the irra-
diation and the repair dynamics also depends on the quality of
damage, it cannot be determined from these experiments if the total
initial number of DBSs was different. The number of particle traver-
sals per cell nucleus can be estimated by the following Equation (1).
D Gyð Þ~LET keV=mmð Þ|W particle=cm2 | 1:610{9 ð1Þ
However, the correlation between nuclear traversals and focus
formation strongly depends on the LET, as at low LET not all particle
traversals would result in a focus, while at higher LET multiple foci
could overlap. The kinetics of DBS repair over 26 h was therefore
used as a measure of the ability of antiprotons to induce challenging
repair substrates. At 26 h after irradiation, only antiproton SOBP
and carbon-ion SOBP treated samples displayed significant residual
damage compared to X-ray treated and control cells (Fig. 2.a). The
frequency ofmicro-foci (Fig. 1c) was analysed qualitatively and is not
included in themean foci/Gy/cell. To test if there was a correlation of
foci size with frequency of residual foci the FWHMwas measured in
foci from all sample sets. The FWHM of the foci was largest for
antiproton SOBP treated cell nuclei at early and late times after
irradiation (Fig. 2.b) while for the other radiation modalities, only
the foci generated by carbon ions at the SOBP showedmorphological
differences at 1 h post irradiation. This supports the hypothesis that
larger foci (or groups of foci) represent DNA lesions that may be
more challenging substrates for the cellular DNA repair machinery.
Indeed, analysis of DNA repair kinetics in these cells (Fig. 2.c) indi-
cated slower rates of DNA repair for antiproton SOBP exposed cells
as well as for carbon ion irradiated samples (both at the proximal and
distal edges of the SOBP) compared to proton and X-ray irradiated
cells.
RBE in the Antiproton Bragg peak. In order to determine cellular
effects of direct clinical relevance, the particle beams investigated
were modulated to produce Spread-Out Bragg Peaks (SOBP) to
mimic clinically relevant situations for moderate sized tumours.
The physical parameters of the employed beams and respective
SOBPs are found in Table 1. LET values have been calculated
using Monte Carlo simulation of the experimental beam set up
with Fluka for the antiproton beam and Geant4 for the proton
and carbon-ion beams. The ability of an antiproton at the mid-
SOBP position to cause a reduction in clonogenic survival was
compared to proton and carbon-ion SOBPs and 225 kVp X-rays
using the same experimental procedure. In our experiments the
biological effectiveness of the antiproton SOBP was intermediate
between that of carbon-ions and protons, conversely the biological
effectiveness of the antiproton plateau was similar to that of X-rays.
Fitting parameters for measured survival curves and calculated RBE
values are found in Table 1. The RBE at 10% survival following
exposure the mid-SOBP for 126 MeV antiproton beam was 1.48 6
0.17, while in the plateau cell killing was comparable to that of
225 kVp X-rays (Fig. 3.a). The RBE at 10% survival for the proton
beam was ,1.2 both proximal to, and in the middle of the SOBP
(Fig. 3.b). Finally, the RBE at 10% survival for the carbon-ion beam
was 2.03 6 0.06 and 3.88 6 0.06 respectively, for the proximal and
distal edges of the SOBP (Fig. 3.c).
Long-range annihilation particles have an RBE similar to X-rays.
Interactions of long-range annihilation products such as pions,
neutrons and gamma rays with cells outside the primary target
are of critical importance as they could alter the highly
conformal dose profile field delivered with an antiproton beam
and produce a wide spread low dose distribution with potential
risks for the patient (Fig. 4.a)22,24. We have therefore attempted to
assess the biological effectiveness of long-range particles in cells
adjacent to our target in the antiproton SOBP region. DNA
damage foci and cell survival were assessed at different distances
from the main beam in order to compare the effects with the ‘‘in
beam’’ responses.
No statistically significant increase in c-H2AX foci compared to
control samples (background of 1.6 6 0.08 foci/cell) was detected at
1 h after irradiation in cells outside the primary beam except for cells
located 28 mm from the centre of the beam when the highest dose
(5.56 Gy) was delivered to the target (Fig. 4.b). In all cases, this is
equal or less than that expected on the basis of the estimated dose to
samples outside the primary beam. The dose at 28 mm from the
beam centre was estimated to be less than 10% of that received by
directly exposed samples for all doses. A qualitative example of the
lateral dose distribution is given in SI Fig. S2, antiproton beam dosi-
metry has been described in detail by Bassler et al.16,14,13).
The impact of secondary particles on cell survival was also
investigated. In this case annihilation secondary particles seem
to have a similar biological effectiveness to X-rays. Although the
data seem to suggest a decrease in the effectiveness per unit dose,
this is not statistically significant. Notably, any cell killing was
only observed when the .5 Gy was delivered to samples at the
beam centre (Fig. 4.c).
These experiments suggest that effective dose to samples outside of
the main antiproton beam falls off very quickly and has a very low
RBE for both cell killing and DNA DSB induction.
www.nature.com/scientificreports
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Discussion
The purpose of the present work is not to discuss the technical and
economic feasibility of antiprotons for cancer radiation treatment
but to provide experimental evidence of the relative biological effec-
tiveness of antiproton exposure to help assess its limits and potential.
Therefore, this study aimed to investigate DNA damage induction/
repair and the resulting cellular effectiveness along the path of a
clinically relevant antiproton beam and in its surroundings and com-
pare this to other clinically relevant radiation modalities currently
used for patient treatment. As DNA damage induction and repair
and biological effectiveness are critical parameters for the successful
utilization of particle beams in radiotherapy, data reported in this
study provides experimental biological evidence upon which the
potential of antiproton beams can be assessed.
DNA damage and survival data indicate that anti-proton anni-
hilation events not only boost the dose in the SOBP but also enhance
the biological effectiveness of the final part of the antiproton path,
without significantly affecting the response in the plateau or in
regions outside the beam trajectory. Our data indicate a correlated
pattern of DNA damage induced by antiprotons in the SOBP. DNA
damage foci in the SOBP appeared larger compared to those pro-
duced in the plateau or by the other radiation beams employed (i.e.
225 kVp X-rays, protons and carbon ions, Fig. 1.a). Intriguingly,
while a trend for larger foci with very high LET particles (up to
Figure 2 | Kinetics of antiproton induced c-H2AX foci. (a) The mean number of foci/cell/Gy was quantified in cells exposed to X-rays, 126 MeV
antiprotons (in plateau or mid-SOBP), 62 MeV protons (proximal to or in the middle of the SOBP) and 62 MeV/u carbon ions (70 or 150 keV/mm. The
data are presented as themean of three independent experiments, normalized to sham irradiated controls. Error bars represent the standard error. (b) The
full-width at half maximum (FWHM, mm) were calculated for foci in 30 nuclei of each group. (c) The foci resolution kinetics was plotted as a measure of
DNA damage repair. Foci were scored in .100 nuclei per slide. The data presented are the mean and standard error.
www.nature.com/scientificreports
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1000 s keV/mm) has been reported previously by other investigators,
our data indicate that foci caused by antiprotons were significantly
larger than those induced by carbon ions despite their modest aver-
age LET (19 keV/mm for antiprotons in the SOBP compared to 70
and 150 keV/mm for carbon ions used in this study) (Fig. 2.b)25.
Therefore, average LET may not be the best parameter to evaluate
biological effectiveness, especially in mixed radiation field situations
such as those occurring following the fragmentation of heavy ions or
annihilation events. By applying high resolution imaging in com-
bination with restoration deconvolution we have shown that anti-
proton SOBP induced foci are morphologically distinct from those
produced by X-rays, protons and carbon ions and contain 2–7 struc-
tures that closely resemble the individual foci of low LET radiation
(Fig. 1.c). As is the case of any ion beam, the majority of the ioniza-
tions resulting from antiproton exposures (,80%) are still caused by
delta electrons. However, the clusters of breaks identified are likely to
be caused by low energy secondary particles generated by the anni-
hilation events. Monte Carlo simulations of annihilation particles
indicate that DSBs near the annihilation vertex are mostly resulting
from particles with Z 5 1 and helium ions. These particles are low
energy (0.16 MeV) protons with LET,71 keV/mm and alpha part-
icles (1.7 MeV/mm) with LET ,72 keV/mm. These two main
responsible particles have a range of 2 and 60 mm, respectively (see
Table 2, the full range of particles is shown in supplementary Fig. 3).
Although other heavier particles are produced, their relative contri-
bution is negligible due to the frequency of their production and their
energy and range being higher. The range of the proposed DSB
inducing particles is such that it may explain the large foci observed
and resolution of clusters of micro-foci that indicate the presence of
distinct DSBs that are spatially correlated. Such particles are gener-
ated with spatial and temporal coincidence that confers a unique
pattern to the DNA damage they produce. Complex DNA lesions
have been described extensively in the literature as breaks of theDNA
structure at the nanometre scale (,10 base pairs) that can be essen-
tially considered as single lesions with implication for the repair
mechanisms due to the proximity of the damage sites. The DNA
lesions described here appear to be of a different nature. In the case
of heavy ions clustered DNA damage is created by high ionization
density along the primary particle path26–31. High LET radiation can
also cause damage over larger distances (i.e. nucleosome and chro-
matin fibre) and still result in single foci, although having a more
relevant impact on the cellular outcome. For antiprotons, we have
shown that despite amodest average LET, correlated DNAdamage is
produced in the Bragg peak region and propose that the large foci in
antiproton SOBP irradiated cell nuclei are a product of the mixed
particle field that is created around antiproton annihilations, and is
not only due to delta electrons. Kreipl and colleagues have predicted
fromMonte Carlo simulations that an increased biological effective-
ness in cases where spatially and temporally overlapping particle
Table 1 | Description of experimental radiation sources used and spread out Bragg peaks employed for antiproton, proton and carbon ion
beams and linear quadratic fitting parameters and RBE for each survival curve
Incident energy
Range in
water (mm)
SOBP mid-point 6
half SOBP depth
(mm)
Sample
position (depth
in water (mm))
Dose av. LET
(keV/mm) a 6 s.e. (Gy21) b 6 s.e. (Gy22)
RBE (SF0.1)
(6 s.e.)
X-ray * 225 kVp n/a n/a n/a ,2 0.61 6 0.1 0.02 6 0.05 1
X-ray ** 225 kVp n/a n/a n/a ,2 0.36 6 0.035 0.054 6 0.005 1
Proton 62 MeV 29.1 18.6 6 10.2 2 ,2 0.57 6 0.06 0.047 6 0.01 1.22 6 0.07
Proton 62 MeV 29.1 18.6 6 10.2 18 ,6 0.53 6 0.05 0.035 6 0.009 1.2 6 0.06
Carbon ion 62 MeV/u 10.8 6.8 6 0.7 3 ,70 0.96 6 0.08 0.094 6 0.03 2.03 6 0.06
Carbon ion 62 MeV/u 10.8 6.8 6 0.7 6.8 ,150 2.04 6 0.092 0 3.88 6 0.05
Antiproton 126 MeV 116.2 100 6 5 23 ,4 0.63 6 0.03 0 0.94 6 0.17
Antiproton 126 MeV 116.2 100 6 5 100 ,19 1.05 6 0.07 0 1.48 6 0.17
*X-ray curve for antiproton RBE calculation, ** X-ray curve for proton and carbon ion RBE calculation.
Figure 3 | Cell survival and RBE estimations. Survival of AG01522 cells as
a function of dose when the cells were irradiated with (a) 126 MeV
antiprotons, (b) 62 MeV protons and (c) 62 MeV/u carbon ions. Error
bars indicate the standard error of measurements from at least two
independent experiments. X-ray, proton and carbon ion measurements
were all performed three times. Antiprotonmeasurements were performed
three times for all doses except the highest two, which were performed
twice. Survival data are fit to a weighted linear quadratic model.
www.nature.com/scientificreports
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tracks occur, can be attributed to an increased DNA lesion complex-
ity, correlation and alteration of radical formation32. It was, however,
concluded that such effects are unlikely to be observed at clinically
relevant doses using high-energy protons. Conversely for antipro-
tons, due to the annihilation products, overlapping tracks may be
expected even at low, clinically relevant, average doses. This conjec-
ture is supported by the foci morphology and repair dynamics and
confirmed by the relatively high RBE values for cell killing observed
in the SOBP of the antiproton beam despite the low average LET.
Taken together, these data represent strong biological evidence that it
Table 2 | Antiproton annihilation products that contribute to pro-
duction of correlated DNA double strand breaks
Particle Energy (MeV/u) Range in water (mm) LET (keV/mm)
Proton 0.16 ,2 ,70
Alpha 1.7 ,60 ,70
Oxygen 1 ,17 ,1000
Figure 4 | Long-range annihilation particles have RBE similar to X-rays. (a) Antiproton-nucleon annihilation produces a number of long range
particles such gamma rays, neutrons and positive, negative and neutral pions. (b) c-H2AX foci were scored in cells positioned directly in the beam at the
mid-point of the SOBP (solid black circle) and in an adjacent flask at either 28 or 42 mm from the centre of the beam (0 mm). A significant increase in
DNA damage was only observed at 1 h after exposure when the in-beam target received 5.56 Gy. P 5 0.026 when compared to mock irradiated control by
student’s T test. Foci were scored in 200 nuclei per sample. (c) Cells were positioned adjacent to in beam samples (approximately 35mm from the centre of
the beam) and were reseeded at clonal density post irradiation in parallel with directly irradiated cells. The dose at 35 mm from the beam centre is
estimated to be ,10% of the dose at the centre of the beam.
www.nature.com/scientificreports
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is possible to achieve an increase in biological effectiveness with low
average LET radiation if the ionizations produced overlap in space
and time.
The induction of large foci by antiproton SOBP observed in this
study correlated with slow repair kinetics (Fig. 2) and enhanced
biological effectiveness for cell killing (Fig. 3). However, it is clear
from our data and from previous studies that a direct correlation
between foci size and cell killing is not always evident and other
factors contribute to variations in foci size25. We report an RBE for
10% survival of 1.48 6 0.17 for the centre of the antiproton SOBP in
AG01522 cells while for carbon ion SOBP the RBE for 10% survival
was 3.88 6 0.06. Additionally, the rate of repair of DNA damage
induced in the antiproton SOBP was slow relative to that induced in
the antiproton plateau or by protons or X-rays but was faster than
carbon ion induced DNA damage. The repair rate of antiproton
SOBP induced DSBs may be more comparable with that observed
in the plateau region of high-energy heavy ions such as reported for
oxygen ions (14 keV/mm)33. From this we conclude that annihilation
induces correlated DNA lesions that are resolved slowly by the cel-
lular DNA repairmachinery due to the temporal coincidence of these
insults and their spatial proximity. However, because the lesions are
individually less complex than those caused by heavier charged part-
icles, they represent a less challenging substrate for DNA repair
machinery than clustered lesions caused by high LET particles such
as carbon ions.
Concerning the overall antiproton SOBPRBE for survival, here we
report an RBE at 10% survival of 1.48 6 0.17 for the centre of the
antiproton SOBP (Fig. 3). This is lower than has been reported for
V79 hamster cells when a 47 MeV antiproton beam was used34–36.
This can be expected due to the higher resistance to conventional
radiation of the V79 rodent cell line, compared to the human fibro-
blast line used in the present study. It has been seen in other studies
that in general a more substantial increase in RBE is observed when
the cell type in question is resistant to cell killing by low LET radi-
ation37. In addition, the SOBP used in our study was deeper and
broader to more closely represent a clinical SOBP however this tends
to dilute the dose-averaged LET38. Cell survival data confirm the
unique quality of damage induced by antiprotons with an RBE in
the entrance channel statistically similar to that measured with pro-
ton and X-ray beams and an enhanced effectiveness (,50%
enhancement) in the centre of the SOBP. More importantly, it is
interesting to compare the ratio of the RBE values at the SOBP and
plateau for the three different particle beams. We observe no differ-
ence for protons (RBESOBP/RBEplateau ,1) but an increase in effec-
tiveness for antiprotons (RBESOBP/RBEplateau,1.5) that is, however,
smaller than what was observed with carbon ions (RBESOBP/
RBEplateau ,1.9).
For carbon ions, it is unlikely that these ratios reflect the clinical
scenario. 70 keV/mm carbon ions may be considered to be more
representative of the proximal part of the SOBP and not a true
plateau that would describe the entrance channel for a clinical beam.
It was not possible to create an SOBP within constraints of this study
that would accurately mimic this. An RBE of 1.2 has been previously
reported for AG01522 cells irradiated in the plateau of a 195 MeV/u
Figure 5 | Simulated dose profiles. Depth and lateral dose profiles for simulated clinically relevant (10 mm SOBP) proton (blue line; 120 MeV), carbon
(green line; 240 MeV/u) and antiproton beams (red line; 120 MeV). Effective dose profiles obtained from the physical dose profiles and considering the
RBESOBP/plateau ratios reported in this work.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 1770 | DOI: 10.1038/srep01770 7
carbon ion beam (RBE ,2.4 in the peak)9 while an RBE of 1.33 has
been reported in the same cell line following irradiation in the plateau
of a 270 MeV/u carbon ion beam (RBE,3.2 in the peak)5. The peak
to plateau ratios are therefore 2 and 2.4 respectively. These ratios
suggest that the actual advantage in terms of cell killing in the target
volume compared to the entrance channel is slightly higher for clin-
ical beams than predicted from data reported here.
Possible clinical implications for the relative increase in effective-
ness for antiprotons (and for protons and carbon ions) will have to be
assessed against the dose profiles that can be obtained with such
beams. Although more extensive and robust experimental data
(including in-vivo investigations) and moreover other factors will
have to be taken into account for accurate clinical evaluations, the
following analysis is aimed to provide an insight on the importance of
correctly estimating the biological effectiveness when dealing with
ion beams. This is summarized in Figure 5. The effective dose profiles
were obtained by multiplying the physical dose calculated via Monte
Carlo simulations by the RBE values reported in this manuscript.
Effective dose profiles for protons and carbon ions are in qualitative
agreement with those reported in literature39 accounting for differ-
ences in the RBE due to the different cell line and experimental
protocols/setup used. These profiles indicate that the increased
RBE of the antiproton end-track helps to sharpen the dose distri-
bution, as expected. However, the increased effectiveness reported
here ismodest and significantly higher dose levels are still expected in
the distal and radial areas around the SOBP compared to protons.
For the beam configurations simulated, while carbon ions exhibited
the sharpest profiles, ,13–15% of the antiproton target dose was
delivered at 5 mm from the edges of the SOBP compared to less than
3% for protons. Across the whole entrance channel (,10 cm), on the
other hand, antiprotons exhibit by far the sharpest dose profiles with
a factor of two reduction in entrance dose compared to protons when
the RBE is considered. The total amount of normal tissue exposed
and also the long term consequences for cells exposed outside the
SOBP region (i.e. RBEplateau for late cellular effects such as mutation
and transformation), also need to be assessed and considered for a
clinical evaluation of the use of antiproton beams. In this respect out-
of-field effects represent also a critical issue and further radiobiolo-
gical studies are necessary in order to correctly evaluate the clinical
implications of these findings.
Finally, with regards to the out-of-field effects observed in this
study, no significant increase in DNA damage over the controls
was observed in the out-of-field samples 1 h post irradiation (except
for the highest dose point and the closest distance). The out-of-field
dose at 3 cm from the beam center is expected to be less than 10% of
the dose delivered to the directly exposed cells (and rapidly decreas-
ing with distance following the 1/r2 trend). This was expected to
result in a small but detectable variation of the biological response
over the background of 1.6 6 0.08 foci/cell.
The lack of DNA damage detected at low doses could be related to
a lower effectiveness of the secondary radiation compared to the
main beam in inducing DNA DSBs and the long irradiation time
(,2 Gy/h) during which cellular metabolic rates are reduced (the
cells were irradiated at 4uC) but are not completely stopped.
Secondary radiation is composed of amixture of radiation (including
some high LET fragments and long range neutrons) with close spa-
tio-temporal relation as produced by individual annihilation events.
DNA damage and survival data, however, clearly demonstrated that
the quality of the damage induced by the out-of-field radiation is not
as severe as that caused by direct exposure to the antiproton beam
and indicated an overall RBE close to 1 for the secondary particles. In
the present study samples were positioned between 28 and 42 mm
outside the antiproton beam. In a previous study using a 47 MeV
antiproton beam, DNA damage detected using the Comet assay
returned to control levels in cell samples positioned just 3 mm distal
to the Bragg peak34. Therefore, while it is accepted that annihilation
particles will contribute to a dose penumbra around the SOBP, the
biological effectiveness of those particles is expected to be low and
their ability to cause measurable DNA damage decreases sharply
with distance from the SOBP.
Methods
Cell culture.AG01522 human fibroblast cells were routinely cultured in T-175 flasks
(NUNC) at 37uC in an atmosphere of 95% air/5% CO2. Cells were grown in filtered
alpha-minimum-essential-medium (AMEM) (LONZA, BioWhittakerH) containing
foetal bovine serum (15%), penicillin (100 IU/ml) and streptomycin (100 mg/ml).
Cells at passage 8 were used in these experiments.
Analysis of DNA damage foci induction and repair. 3 3 105 cells were seeded in
slide flasks (NUNC) and allowed to adhere for at least 6 h. For irradiations the slide
flasks were filled with fresh culture medium chilled to 4uC. Samples were maintained
at 4uC during the irradiation and for up to 24 h. Post irradiation, cold media was
replaced with 3 mL warmmedia per slide flask. Cells were then incubated at 37uC for
1 to 24 h, then fixed in ice-cold methanol/acetone (151) for 20 min. Fixed cells were
washed once in PBS then permeabilized with PBS/0.5% TritonHX-100 (Sigma-
Aldrich) for 20 min at 4uC; non-specific binding was blocked with PBS/0.2%
skimmedmilk/5% foetal bovine serum/0.1%TritonHX-100 for 1 h at 20uC. Cells were
incubated for 1 h at 20uC with anti-phospho-H2AX (1510000 dilution, mouse
monoclonal antibody, clone JBW301, Upstate Biotechnology). Cells were washed
twice in PBS/0.1% TritonHX-100 and then incubated for 1 h at 4uC in the dark with
Alexa FluorH 488 goat anti-mouse IgG cross-absorbed antibody (152000 dilution,
Molecular Probes). Cells were washed twice in PBS/0.1% TritonHX-100 and then
rinsed in PBS. Slides were mounted with Vectashield mounting medium containing
49,6-diamidino-2-phenylindole (DAPI) (Vector Labs, UK). Nail varnish was used to
attach cover slips to slides. Samples were scored and images acquired using a Carl
ZEISS Axiovert 200 M fluorescence microscope with CCD acquisition capability and
Axiovision Rel. 4.6 software. An x63 magnification oil immersion objective was
employed for scoring foci by eye. Foci were scored in 100–200 cell nuclei per sample.
The scorer was blinded to the sample treatment. Unless otherwise stated all data are
mean and standard error of three independent experiments. The background number
of foci in sham-irradiated controls was 1.6 6 0.08 foci/cell. Dose response curves
were fitted using non-linear regression and linear regression analyses programs in
Graph pad 4.0 software (Prism).
Foci analysis. Images of ionizing radiation-induced foci (RIF) from at least 20 cells
were imported into Image J40. Intensity profiles were plotted and used to determine
the full width at the maximum intensity (FWHM) for each focus. FWHM was
calculated for at least 30 foci in each group analyzed.
Cellular survival measurements. 33 104 cells were seeded in 30 mL of culture media
in single spots (,3–4 mm diameter) in sterile, dry slide flasks (NUNC). These cells
were allowed to adhere for 6–8 h at 37uC. Culture media was removed and cells
washed with 2 mL warm sterile PBS before 4 mL of warm media was added to each
slide flask for incubation at 37uC for a further 10 h.
Prior to irradiation the slide flasks were filled with cold sterile culture medium.
Cells were maintained at 4uC for up to 24 h. A time course for the duration that the
cells were maintained at that temperature was carried out to confirm that this would
not significantly alter the cells plating efficiency (PE). Post irradiation cells were
detached by addition of 300 mL of 1 3 Trypsin EDTA for 5 min. 2 mL of culture
medium was then added. The cell suspensions were pipetted carefully to achieve
single cell suspensions. Cells were seeded into six well plates (NUNC) with densities
calculated to achieve approximately 50 colonies per well. Within each experiment
three wells were plated for each density and each dose point (technical replicates).
Each experiment was performed three times for each radiation type. The plates were
then incubated at 37uC in an atmosphere of 5% CO2 and 95% humidity for 7 to 10
days or until macroscopic colonies containing at least 50 cells could be observed.
Colonies were then fixed in 100%methanol and stained with crystal violet (1% in 80%
methanol).
For carbon ion and proton beam irradiations AG01522 cells were detached from
the flask with trypsin EDTA (0.5 w/v% in sterile PBS) and the concentration of the
resulting cell suspension measured using a haemocytometer. The stock suspension
was diluted in fresh culture media to obtain a concentration of,5000 cells/ml. Single
cells were seeded in T25 flasks (NUNC) at densities calculated to give approximately
100 colonies per flask. The cells were incubated for 12–18 h at 37uC to allow single
cells to attach before irradiation. 30 min prior to irradiation, sample flasks were
removed from the incubator and filled with pre-warmed culture medium. Dose
increments were delivered to achieve cellular surviving fractions of around 0.9, 0.5,
0.1 and 0.01. Post irradiation culture medium was aspirated to leave 7 ml per flask
and flasks were subsequently incubated at 37uC for 10 days.
Reference X-ray survival curves that were used for proton and carbon ion RBE
calculation were produced following this protocol. In all experiments the plating
efficiency of AG01522 cells was 15–20%.
Antiproton irradiation. Cells were suspended in a phantom containing 18.5%
glycerine in water. The temperature of the liquid was controlled electronically and
maintained at 4uC. Samples were positioned perpendicular to a 126 MeV antiproton
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beam delivered by the CERN Antiproton decelerator (AD) at a dose rate of
12–17 mGy/min in the plateau. Plateau doses ranged from 0 to 2 Gy. Monte Carlo
dosimetry simulations using the FlukaMC particle transport code were confirmed by
analysis of irradiated alanine stacks and ionization chambers13. Spread out antiproton
Bragg peaks were achieved by sequentially degrading the beam with PMMA
degraders. The dose average LET in the plateau is ,4 keV/mm and in the SOBP is
,19 keV/mm. The dosimetry is described in detail elsewhere35. The antiproton beam
intensity is well described by a Gaussian shape in the plane perpendicular to the beam
with s 5 4.75 mm with divergence of 0.5 degrees. Direct exposed samples were
confined to a ,4 mm diameter spot across which the dose and LET were uniform
within 15%. Out-of-field dose was estimated using Monte Carlo simulations and
found to be ,10% of the in-field-dose at 30 mm from the centre of the antiproton
beam. Out-of-field dose at this distance from the main beam is mainly due to
secondary radiation produced by the annihilation events with less than 7% due to
scattered or diverging antiprotons (TRIM simulation). Sample-beam alignment was
performed using Gafchromic films and laser reference beams.
Proton and carbon ion beam irradiations. 62 MeV/nucleon proton and carbon ion
beams were produced by the super-conducting cyclotron at the CATANA facility in
the INFN-LNS in Catania, Italy. Dosimetry was performed using aMarkus ionization
chamber (Type 34045, PTW, Freiburg, Germany). The monoenergetic beams
produced were degraded by a clinical rangemodulator (for protons) and a ripple filter
(for carbon ions) to create spread-out Bragg peaks. The average LETwas,2 keV/mm
in the entrance and,6 keV/mm across the SOBP for the proton beam and,70 keV/
mm in the proximal part, and ,150 keV/mm in the distal part of the SOBP for the
carbon ion beam. Samples were irradiated at a dose rate of 1–3 Gy/min at room
temperature. The beam lines and dosimetry are previously described37,41.
X-ray irradiation. Cell were irradiated using an ‘XRAD225’ 225 kV X-ray cabinet
fitted with a 2 mm copper filter (Precision X-ray Inc., CT, USA). The instrument was
calibrated with a secondary standard electrometer and chamber. Doses of 0 to 8 Gy
were delivered to cell samples with a dose rate of 0.54 Gy/min and at a distance of
50 cm from the source. Control samples were mock irradiated under the same
conditions.
Monte carlo simulations. Dose-depth and lateral dose curves were generated using
Geant442 simulating energy deposited by 100 mm side square beams of protons,
antiprotons and carbon ions in a water. Energy range 120–126 MeV was used for
protons and antiprotons and 227–239 MeV/u for carbon ions in order to generate
1 cm SOBP. Dose-depth curves were scored in a 23 2 cm2 around the beam axis and
lateral dose curves were scored in a 1 cm deep region across the SOBP. Effective dose
profiles have been obtained by assuming RBESOBP/RBEEntrance 5 1.1 for protons and
1.5 for antiprotons. The SOBP regions were identified as areas with normalized
physical dose .90% and within 50 mm radial distance. For carbon-ion beam, the
RBE was assumed to linearly increase with the LET in the range 20–150 keV/mm as
suggested by a review of data available in literature43 from an initial RBEEntrance 5 1.5
to an RBESOBP 5 3.9, as determined in this work.
Statistical analysis. Sample sets for the different radiation modalities were compared
by unpaired two-tailed T tests. It was assumed that the foci number per nucleus and
focus size would be distributed normally within each sample. P values of less than 0.05
were considered to indicate that sample means were significantly different.
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